Cardiovascular
Novo Nordisk and Evotec launch translational drug discovery accelerator
Novo Nordisk has entered a partnership with Evotec to kickstart a drug discovery accelerator called LAB eN² that will combine the…
Novo Nordisk and Valo to develop cardiometabolic disease therapies
Novo Nordisk has signed an agreement with Valo Health for the discovery and development of new therapies to treat cardiometabolic diseases. The…
Boehringer and Lilly gain FDA approval for kidney disease therapy
Boehringer Ingelheim and Eli Lilly and Company have received approval from the US Food and Drug Administration (FDA) for Jardiance…
Hasten and LIB Therapeutics enter $325m CVD drug development deal
Hasten Biopharmaceutical has signed an agreement to acquire the rights for the development and commercialisation of LIB Therapeutics’ cardiovascular disease (CVD) drug…
Novo Nordisk and Broad Institute to explore drug targets for diabetes, CMDs
Novo Nordisk has entered a research collaboration with the Broad Institute of Massachusetts Institute of Technology and Harvard to detect…
New 2023 guidelines for the management of cardiomyopathies
A new set of European Society of Cardiology (ESC) guidelines was shared at the 2023 ESC conference in Amsterdam, Netherlands.…
AstraZeneca receives China’s NMPA approval for Forxiga
AstraZeneca has received approval from China’s National Medical Products Administration (NMPA) for Forxiga (dapagliflozin) to reduce the risk of cardiovascular mortality,…
Innovent receives approval from China’s NMPA for SINTBILO
Innovent Biologics has secured approval from China's National Medical Products Administration (NMPA) for SINTBILO (tafolecimab injection, anti-PCSK9 monoclonal antibody) to…
Ionis and Novartis to develop medicine for cardiovascular disease
Ionis Pharmaceuticals has signed a collaboration and licence agreement with Novartis to advance a next-generation programme targeting lipoprotein(a) (Lp(a)) for…
Boehringer and Lilly secure EC approval for Jardiance to treat adults with CKD
Boehringer Ingelheim and Eli Lilly have secured approval from the European Commission (EC) for Jardiance (empagliflozin) to treat adults with…